GlassScriptPhysician profile
Michael Fink
NPI 1215621651
$233.01
in general payments reported to CMS, 2019-2025
8 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $22.29 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $66.53 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $36.52 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.53 | 2025 | Caplyta |
| Seqirus USA INC | $25.46 | 2025 | Flucelvax, Fluad |
| Inspire Medical Systems, INC. | $24.41 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.21 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $18.71 | 2025 | Vaxelis, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $14.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.